About FDA

CDER Leadership Bios

Footer graphic-CDER Leadership 

Janet Woodcock
Janet Woodcock, M.D.
Director, Center for Drug Evaluation & Research

Janet Woodcock is Director of the Center for Drug Evaluation and Research (CDER), at the Food and Drug Administration (FDA). As of January 2015, Dr. Woodcock also assumed the role of Acting Director of CDER’s newly formed Office of Pharmaceutical Quality, (OPQ).

(more)

Douglas Throckmorton
Douglas Throckmorton, M.D.
Deputy Center Director for Regulatory Programs

As Deputy Director for Regulatory Programs, Dr. Throckmorton shares the responsibility for overseeing the regulation of research, development, manufacture and marketing of prescription, over-the-counter, and generic drugs in the United States. He is committed to ensuring that the benefits of approved drugs outweigh their known risks. 

(more)

Robert Temple
Robert Temple, M.D.
Deputy Center Director for Clinical Science

Robert Temple serves as CDER's Deputy Center Director for Clinical Science and also Acting Deputy Director of the Office of Drug Evaluation I (ODE-I). He has served in this capacity since the office's establishment in 1995.  

(more)

Richard Moscicki

Richard A. Moscicki, M.D.
Deputy Center Director for Science Operations

Richard (Rich) A. Moscicki (Mo-shis-ke), M.D., joined the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), as Deputy Center Director for Science Operations in April of 2013. In this position, Dr. Moscicki is responsible for executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER’s programs.

(more)

Jane Axelrad
Jane Axelrad, JD
Associate Director for Policy, CDER

Jane Axelrad, the Associate Director for Policy, CDER, serves as the Agency lead on managing policy, surveillance and enforcement, legislative, and oversight issues related to pharmacy compounding arising out of the meningitis outbreak. She also manages other high-priority projects that cut across office lines.  

(more)

Theresa Toigo
Theresa A. Toigo, MBA, RPh
Associate Director for Drug Safety Operations

Theresa (Terry) Toigo serves as CDER’s Associate Director for Drug Safety Operations. She is responsible for the management of significant and timely drug safety issues, as well as the creation and oversight of CDER processes for management of cross-office and cross-Center safety issues. 

(more)

ShaAvhree Buckman
ShaAvhrée Buckman-Garner, M.D., Ph.D., FAAP
Director, Office of Translational Sciences

ShaAvhrée Buckman-Garner, M.D., Ph.D., FAAP is the Director of CDER's Office of Translational Sciences (OTS). OTS is comprised of the Office of Biostatistics, Office of Clinical Pharmacology, Office of Computational Science, Office of Study Integrity and Surveillance, provides oversight to CDER research involving human subjects, the CDER ORISE Program, as well as CDER regulatory science research. OTS is responsible for providing coordination for Critical Path initiatives across CDER in partnership with individual CDER offices.

(more)

Mary Beth Clarke
Mary Beth Clarke
Director, Office of Executive Programs

As Director of the Office of Executive Programs, Mary Beth Clarke oversees a variety of Center-wide programs, including an executive project management staff, the Center’s executive secretariat function, the scientific advisory committee program, the Division of Training & Development, the office of the CDER ombudsman.

(more)

Gerald Dal Pan
Gerald Dal Pan, M.D., M.H.S.
Director, Office of Surveillance and Epidemiology

Gerald J. Dal Pan became the Director of the Office of Surveillance and Epidemiology (known then as the Office of Drug Safety) in November 2005. Before that, he was the Director of the Division of Surveillance, Research, and Communication Support.

(more)

Grail Sipes
Grail Sipes, JD
Director, Office of Regulatory Policy

Grail Sipes is the Director of CDER’s Office of Regulatory Policy (ORP), which is responsible for managing the development of new regulations and policies applicable to FDA’s regulation of human pharmaceuticals, including preparing responses to citizen petitions.

(more)

John Jenkins
John Jenkins, M.D.
Director, Office of New Drugs

John Jenkins joined FDA as a medical officer in the Division of Oncology and Pulmonary Drug Products in 1992. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the newly created Division of Pulmonary Drug Products in 1995.

(more)

Melanie Keller
Melanie Keller, MBA
Director, Office of Management

Melanie Keller joined CDER in December 2010 as Executive Officer and Director of CDER's Office of Management. Before that, she served as the Executive Officer at the Center for Science Review (CSR) at the National Institutes of Health (NIH).

(more)

Theresa Mullin
 
Theresa M. Mullin, Ph.D.
Director, Office of Strategic Programs

Theresa M. Mullin directs strategic programs including business informatics for CDER. The Office of Strategic Programs plays a lead role in a number of CDER’s strategic initiatives and modernization efforts including development of benefit-risk and other decision support tools, the international program, data standardization, lean management, program analysis, informatics, and major user fee negotiations.

(more)

Jonathan Jarow, M.D.
Jonathan Jarow, M.D.
Acting Director, Office of Medical Policy

As Acting Director of CDER’s Office of Medical Policy, Jonathan Jarow, M.D. is responsible for developing, coordinating, and implementing medical policy programs and strategic initiatives.

(more)

Cynthia Schnedar
Cynthia Schnedar, JD
Director, Office of Compliance

As Director of CDER’s Office of Compliance, Cynthia Schnedar, J.D., leads efforts to protect the American public from unsafe and ineffective drug products by ensuring that companies comply with federal standards for quality and safety.

(more)

Christine Shreeve
Christine Shreeve
Director, Office of Communications

Christine Shreeve is Director of CDER’s Office of Communications (OCOMM). She oversees CDER’s public outreach and internal communications programs. Ms. Shreeve’s expertise includes communications strategy, strategic planning and evaluation, coalition building, policy analysis, communications program managements, writing, and media relations.

(more)

Kathleen Uhl

Kathleen Uhl, M.D.
Director, Office of Generic Drugs

Kathleen (Cook) Uhl, M.D. serves as the Director for the Office of Generic Drugs in the Center for Drug Evaluation and Research. This office is responsible for the review and approval of Abbreviated New Drug Applications (ANDAs).
(more)

Janet Woodcock
Janet Woodcock, M.D.
Acting Director, Office of Pharmaceutical Quality

Janet Woodcock, M.D., is director of the Center for Drug Evaluation and Research (CDER) and also serves as acting director of CDER’s Office of Pharmaceutical Quality (OPQ). OPQ combines non-enforcement-related drug quality work into one super-office, creating one quality voice and improving FDA’s oversight of quality throughout the lifecycle of a drug product.

(more)

Rosemary Roberts 
Rosemary Roberts, M.D.
Director, Counter-Terrorism and Emergency Coordination Staff

Dr. Rosemary Roberts is the Director for the newly realigned Staff, renamed Counter-Terrorism and Emergency Coordination Staff (CTECS) in the Office of the Center Director, as of September 2014. Prior to the realignment, Dr. Roberts was the Director of the Office of Counter-Terrorism and Emergency Coordination (OCTEC) from September 2004 to September 2014. CTECS works with sponsors developing countermeasures against chemical, biological, radiological and nuclear (CBRN) threats prior to the pre-IND stage. In addition, CTECS is the FDA point of contact for the Strategic National Stockpile (SNS) which is maintained by the CDC. CTECS is also responsible for coordinating emergency preparedness and response for CDER.

(more)

 

Footer graphic-CDER Leadership 

Page Last Updated: 05/19/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.